AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Jetstar to Charge for Overhead Cabin Bags From February 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
VANCOUVER, British Columbia and WARMINSTER, Pa., March 12, 2018 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Wednesday, March 14, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss fourth quarter 2017 year-end financial results and provide a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 8777644.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
